Fredun [FREDUN] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Fredun Pharmaceuticals Ltd. wins in 8 metrics, Sun Pharmaceutical Industries Ltd. wins in 12 metrics, with 0 ties. Sun Pharmaceutical Industries Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Fredun Pharmaceuticals Ltd. | Sun Pharmaceutical Industries Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 29.83 | 36.73 | Fredun Pharmaceuticals Ltd. |
| Price-to-Book Ratio | 6.26 | 5.15 | Sun Pharmaceutical Industries Ltd. |
| Debt-to-Equity Ratio | 108.78 | 6.68 | Sun Pharmaceutical Industries Ltd. |
| PEG Ratio | 0.31 | 3.59 | Fredun Pharmaceuticals Ltd. |
| EV/EBITDA | 13.98 | 23.61 | Fredun Pharmaceuticals Ltd. |
| Profit Margin (TTM) | 5.53% | 19.21% | Sun Pharmaceutical Industries Ltd. |
| Operating Margin (TTM) | 15.26% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| EBITDA Margin (TTM) | 15.26% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| Return on Equity | 13.96% | 15.08% | Sun Pharmaceutical Industries Ltd. |
| Return on Assets (TTM) | 4.05% | 11.87% | Sun Pharmaceutical Industries Ltd. |
| Free Cash Flow (TTM) | $-351.69M | $119.44B | Sun Pharmaceutical Industries Ltd. |
| Dividend Yield | 0.09% | 0.97% | Sun Pharmaceutical Industries Ltd. |
| 1-Year Return | 183.86% | 7.10% | Fredun Pharmaceuticals Ltd. |
| Price-to-Sales Ratio (TTM) | 1.93 | 7.05 | Fredun Pharmaceuticals Ltd. |
| Enterprise Value | $11.27B | $3,783.37B | Sun Pharmaceutical Industries Ltd. |
| EV/Revenue Ratio | 1.91 | 6.66 | Fredun Pharmaceuticals Ltd. |
| Gross Profit Margin (TTM) | 28.72% | 80.96% | Sun Pharmaceutical Industries Ltd. |
| Revenue per Share (TTM) | $1,273 | $237 | Fredun Pharmaceuticals Ltd. |
| Earnings per Share (Diluted) | $69.90 | $45.46 | Fredun Pharmaceuticals Ltd. |
| Beta (Stock Volatility) | 0.46 | 0.11 | Sun Pharmaceutical Industries Ltd. |
Fredun Pharmaceuticals Ltd. vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Fredun Pharmaceuticals Ltd. | 0.17% | 0.73% | -2.19% | 43.43% | 39.40% | 50.67% |
| Sun Pharmaceutical Industries Ltd. | -0.09% | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Fredun Pharmaceuticals Ltd. | 183.86% | 158.56% | 447.18% | 11,453.75% | 18,386.00% | 18,386.00% |
| Sun Pharmaceutical Industries Ltd. | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
Performance & Financial Health Analysis: Fredun Pharmaceuticals Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | FREDUN | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹11.55B | ₹3.88T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 11,259 | 3,903,142 |
| 90 Day Avg. Volume | 9,301 | 3,253,866 |
| Last Close | ₹2,314.65 | ₹1,806.00 |
| 52 Week Range | ₹791.00 - ₹2,620.00 | ₹1,548.00 - ₹1,916.60 |
| % from 52W High | -11.65% | -5.77% |
| All-Time High | ₹2,620.00 (May 25, 2026) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -11.65% | -7.87% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.57% | 0.14% |
| Quarterly Earnings Growth | 0.97% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.19% |
| Operating Margin (TTM) | 0.15% | 0.26% |
| Return on Equity (TTM) | 0.14% | 0.15% |
| Debt to Equity (MRQ) | 108.78 | 6.68 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹333.11 | ₹324.46 |
| Cash per Share (MRQ) | ₹18.49 | ₹115.87 |
| Operating Cash Flow (TTM) | ₹-1,140,997,000 | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹197.39M | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.09% | 0.97% |
| Last 12-Month Dividend | ₹0.70 | ₹16.50 |
Valuation & Enterprise Metrics Analysis: Fredun Pharmaceuticals Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | FREDUN (Apr 24, 2026) | SUNPHARMA (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 29.83 | 36.73 |
| Forward P/E | N/A | 29.48 |
| PEG Ratio | 0.31 | 3.59 |
| Price to Sales (TTM) | 1.93 | 7.05 |
| Price to Book (MRQ) | 6.26 | 5.15 |
| Market Capitalization | ||
| Market Capitalization | ₹11.55B | ₹3.88T |
| Enterprise Value | ₹11.27B | ₹3.78T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.91 | 6.66 |
| Enterprise to EBITDA | 13.98 | 23.61 |
| Risk & Other Metrics | ||
| Beta | 0.46 | 0.11 |
| Book Value per Share (MRQ) | ₹333.11 | ₹324.46 |
Financial Statements Comparison: Fredun Pharmaceuticals Ltd. vs Sun Pharmaceutical Industries Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | FREDUN (2025) | SUNPHARMA (2025) |
|---|---|---|
| Revenue/Sales | 4.52B | 520.41B |
| Cost of Goods Sold | 3.45B | 121.98B |
| COGS % of Revenue | 76.5% | 23.4% |
| Gross Profit | 1.06B | 398.44B |
| Gross Margin | 23.5% | 76.6% |
| Research & Development | 49.76M | N/A |
| Operating Income (EBIT) | 475.31M | 125.81B |
| Operating Margin | 10.5% | 24.2% |
| EBITDA | 530.69M | 167.25B |
| EBITDA Margin | 11.7% | 32.1% |
| Pre-Tax Income | 274.94M | 137.52B |
| Pre-Tax Income % of Revenue | 6.1% | 26.4% |
| Income Tax | 77.54M | 27.72B |
| Income Tax % of Revenue | 1.7% | 5.3% |
| Net Income (Profit) | 197.39M | 109.65B |
| Profit Margin | 4.4% | 21.1% |
Balance Sheet & Liquidity Metrics
| Metric | FREDUN (2025) | SUNPHARMA (2025) |
|---|---|---|
| Cash & Equivalents | 6.37M | 102.69B |
| Total Current Assets | 4.28B | 526.24B |
| Total Current Assets % of Revenue | 94.7% | 101.1% |
| Total Current Liabilities | 3.28B | 181.94B |
| Total Current Liabilities % of Revenue | 72.6% | 35.0% |
| Long-Term Debt | 96.13M | 3.58B |
| Long-Term Debt % of Revenue | 2.1% | 0.7% |
| Total Shareholders Equity | 1.41B | 724.86B |
| Retained Earnings | 628.39M | 578.62B |
| Retained Earnings % of Revenue | 13.9% | 111.2% |
| Property, Plant & Equipment | 95.24M | 100.36B |
Cash Flow Statement Comparison
| Metric | FREDUN (2025) | SUNPHARMA (2025) |
|---|---|---|
| Operating Cash Flow | -1.14B | 110.84B |
| Operating Cash Flow % of Revenue | -25.3% | 21.3% |
| Capital Expenditures | -59.94M | -20.68B |
| Free Cash Flow | -351.69M | 119.44B |
| FCF Margin | -7.8% | 23.0% |
| Debt Repayment | N/A | -43.44B |
| Common Stock Repurchase | N/A | -29.00B |
Short Interest & Institutional Ownership Analysis
| Metric | FREDUN | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 5.47M | 2.40B |
| Float Shares | 534,241 | 1.07B |
| % Held by Insiders | 53.36% | 55.62% |
| % Held by Institutions | 0.00% | 28.69% |
| % Held by Public | 46.64% | 15.69% |
Dividend Analysis & Yield Comparison: Fredun Pharmaceuticals Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | FREDUN | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹0.70 | ₹16.50 |
| Last 12-Month Dividend Yield | 0.09% | 0.97% |
| 3-Year Avg Annual Dividend | ₹0.70 | ₹17.33 |
| 3-Year Avg Dividend Yield | 0.08% | 0.51% |
| 3-Year Total Dividends | ₹2.10 | ₹52.00 |
| Ex-Dividend Date | Sep 23, 2024 | Feb 05, 2026 |